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Apparent diffusion coefficient 
as a prognostic factor in clival 
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Clival chordoma is a rare disease with high recurrence rates even after a combination of surgical 
resection and radiotherapy. Apparent diffusion coefficient (ADC) has been used to evaluate aggressive 
features of chordoma, but its utility for clival chordoma has not been explored specifically. In this 
study, the utility of preoperative ADC values was analyzed for predicting tumor progression and 
recurrence in patients with clival chordoma. Between 2012 and 2019, a total of 30 operated cases were 
analyzed with available preoperative ADC data. Receiver operating characteristic (ROC) analysis was 
used to obtain ADC cutoff values for predicting tumor aggressiveness. The mean and minimum ADC 
values were significantly lower in the aggressive tumor group than in the stable tumor group (both 
P < 0.001). ROC analysis showed that a mean cutoff ADC value of 1198 × 10−6  mm2/s and minimum ADC 
value of 895.5 × 10–6  mm2/s could be used to predict aggressive features of clival chordoma. Subtotal 
resection, partial resection, and mean and minimum ADC values that were lower than cutoff values 
were negative predictors of overall survival and progression‑free survival. In conclusion, mean and 
minimum ADC values could be useful in predicting aggressiveness of clival chordoma.
Clival chordoma is a rare and slow-growing disease that infiltrates the bone and extends into the adjacent soft 
tissue, especially to the  brainstem1. Such chordomas show malignant behavior with high recurrence rates even 
after treatment with the combination of maximal safe surgical resection and adjuvant  radiotherapy2. Further-
more, adjacent neurovascular structures make it difficult to eradicate the tumor  surgically3,4. To overcome these 
locally invasive properties of chordoma, several studies have examined the efficacy of chemotherapeutic agents 
for treating chordoma, but none were successful for clinical  use5–8. Brachyury, a targeting transcription factor 
is one example that has shown to be effective, but clinical application is still  limited6. Particle beam radiation 
(proton or carbon ion based) has been introduced into chordoma treatment, but its efficacy over conventional 
radiation remains  controversial9–12.
Many studies have investigated prognostic factors of clival chordoma, but the understanding of the disease 
is still limited due to its rarity and cancer biology. Previous studies have revealed that tumor size, location, and 
extent of resection (EOR) are associated with overall survival (OS) and progression-free survival (PFS) in clival 
 chordoma4,13,14. However, there are still no reliable factors that could predict the behavior of the tumor before 
treatment begins.
A recent study revealed that apparent diffusion coefficient (ADC) values could be used to predict tumor 
progression for craniospinal axis  chordomas15. The study, however, covered both clival and sacral chordomas, 
included only a small number of patients, and did not take EOR into consideration, which is still, the most reliable 
prognostic factor for clival chordoma. In this study, we evaluated the aggressiveness of clival chordomas using 
preoperative ADC  values16 and determined ADC cutoff values to predict tumor progression and recurrence.
Results
Clinical characteristics of chordoma patients. There were 16 male (53.3%) and 14 female (46.7%) 
patients with a mean age of 48.9 years (range 24–76 years). Histologically, two cases were diagnosed as chon-
droid chordoma and 28 cases as classic chordoma. Gross total resection (GTR) was achieved in 12 cases (40%), 
near-total resection (NTR) in 10 cases (33.3%), subtotal resection (STR) in 6 cases (20%), and partial resection 
OPEN
1Department of Neurosurgery, Gangnam Severance Hospital, College of Medicine, Yonsei University, 211 Eonju-ro, 
Gangnam-gu, Seoul 06273, Republic of Korea. 2Department of Pathology, Gangnam Severance Hospital, College 
of Medicine, Yonsei University, Seoul, Republic of Korea. 3Department of Radiology, Gangnam Severance Hospital, 
College of Medicine, Yonsei University, Seoul, Republic of Korea. *email: NSHHP@yuhs.ac
2
Vol:.(1234567890)
Scientific Reports |          (2021) 11:486  | https://doi.org/10.1038/s41598-020-79894-8
www.nature.com/scientificreports/
(PR) in 2 cases (6.7%). Seventeen cases (56.7%) underwent adjuvant intensity-modulated radiotherapy and 13 
cases (43.3%) underwent proton-beam radiotherapy.
There were 21 cases in the stable group (70%) and 9 cases (30%) in the aggressive group. Patient and tumor 
characteristics are summarized in Table 1. The mean (P < 0.001), maximum (P = 0.012), and minimum (P < 0.001) 
ADC values were significantly lower in the aggressive than in the stable tumor group (Fig. 1). The interclass 
correlation coefficient for interobserver reliability of mean ADC values was 0.925 (95% CI, 0.843–0.967). The 
rates of GTR and NTR were significantly higher in the stable than in the aggressive group (P = 0.003). The mean 
number of surgical resections was higher in the aggressive than in the stable group (P = 0.002). There were no 
differences in sex, age, histology, and the type of adjuvant radiotherapy received between the two groups.
Preoperative ADC values for predicting aggressiveness of clival chordoma. According to ROC 
analysis, the ADC cutoff values that distinguished the aggressive from the stable tumor group were as follows: 
mean 1198 × 10–6  mm2/s, sensitivity of 0.89, specificity of 0.81, area under the curve of 0.873 (P = 0.001; 95% CI, 
0.748–0.998), maximum 1695 × 10–6  mm2/s, sensitivity of 0.89, specificity of 0.62, and area under the curve of 
0.796 (P = 0.011; 95% CI, 0.631–0.962), and minimum 895.5 × 10–6  mm2/s, sensitivity of 1, specificity of 0.81, and 
area under the curve of 0.899 (P = 0.001; 95% CI, 0.787–1.000) (Fig. 2).
Preoperative ADC values for predicting PFS and OS of clival chordoma. Four patients died dur-
ing a mean follow-up of 30 months (range, 1–98 months). The predictive factors associated with PFS of clival 
chordoma are shown in Table 2. Log-rank tests revealed that a mean ADC value ≤ 1198 × 10–6  mm2/s (P < 0.001), 
a minimum ADC value ≤ 716.5 × 10–6  mm2/s (P < 0.001), and maximum value ADC ≤ 1695 × 10–6  mm2/s 
(P = 0.017) correlated with a poor PFS (Fig. 3). GTR and NTR were associated with an improved PFS (P = 0.001). 
Other variables such as brain stem extension, MRI enhancement pattern, and the type of adjuvant radiotherapy 
received had no significance on PFS. Kaplan–Meier survival analysis showed that EOR (STR and PR) (P = 0.049), 
mean ADC value ≤ 1198 × 10–6  mm2/s (P = 0.024), and minimum ADC value ≤ 716.5 × 10–6  mm2/s (P = 0.003) 
were significantly associated with a poor OS. A lower maximum ADC value had a trend toward a shorter OS 
(P = 0.062).
Discussion
Clival chordoma is a rare, primary bone tumor arising from notochord  remnants17,18. It can infiltrate various areas 
of the skull base such as the upper, middle and lower clivus, cavernous sinus, petrous bone, and upper cervical 
spine with or without intradural  invasion13. Complete surgical resection is a challenge considering the deep-
seated location of the tumor and the close proximity to critical neurovascular structures. In general, a maximal 
safe surgical resection followed by adjuvant radiotherapy is recommended, but standardized guidelines are lim-
ited owing to the rarity of the  disease17,19,20. So far, no chemotherapeutic agents are clinically applicable and the 
choice of radiation modalities remains  controversial9–11. For better understanding of the disease, several studies 
have investigated prognostic factors such as EOR, histopathology, and radiation  modality2,14,21. Unfortunately, 
there are no preoperative factors that can predict the tumor behavior. In the present study, we performed an 
analysis of 30 consecutive cases using the known prognostic factors and additionally hypothesized that preopera-
tive ADC values could be useful in predicting the aggressiveness of clival chordomas.
ADC values have been reported to be diagnostic and prognostic for central nervous system  tumors22–24. 
For example, a lower mean ADC value has been known to correlate with high cellularity and mitoses in 
 meningioma25. Thus, ADC maps could be applied to predict the grade of meningioma before  surgery24,26. 
Recently, Yeom et al. reported that poorly de-differentiated chordomas have a lower mean, maximum, and 
minimum ADC values compared to classic and chondroid  chordomas27. A lower mean ADC value has also 
been reported to predict OS for craniospinal axis  chordomas15. Our results were consistent with the findings of 
previous reports that preoperative ADC values could be used to infer to the characteristics of tumor components 
and predict the behavior of clival chordoma. Diffusion measurement correlates with intra- and extra-cellular 
Table 1.  Case demographics and clinical characteristics.  ADC apparent diffusion coefficient, GTR gross total 
resection, MRI magnetic resonance imaging, NTR near total resection, SD standard deviation. Variables are 
presented as mean ± standard deviation or number (percent).
Aggressive group (N = 9) Stable group (N = 21) P-value
Age at first operation (year) 42.11 ± 14.54 51.81 ± 13.37 0.087
Male 6 (66.7%) 10 (47.6%) 0.440
Pathology (Classic chordoma) 8 (88.9%) 20 (95.2%) 0.517
Extent of tumor removal (GTR + NTR) 3 (33.3%) 19 (90.5%) 0.003
Radiotherapy (Proton) 4 (44.4%) 9 (42.9%) 1
Brainstem extension (at first MRI) 9 (100%) 15 (71.4%) 0.141
Average operation number (number/patient) 2.67 ± 1.32 1.19 ± 0.40 0.002
Mean ADC  (10−6  mm2/s) 1091.78 ± 147.59 1411.24 ± 256.74  < 0.001
Maximum ADC  (10−6  mm2/s) 1485.44 ± 190.06 1757.90 ± 274.14 0.012
Minimum ADC  (10−6  mm2/s) 702.11 ± 144.95 1125.43 ± 301.78  < 0.001
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water  movement28. Hypercellular areas have lower ADC values from reduced water  motion29. Microscopically, 
classic chordoma has a low mitotic activity and a moderate cellular component within the myxoid stroma and 
chondroid chordoma has large components of cartilaginous materials in  matrices30. Although chordomas have 
common histopathologic characteristics, their ADC values may differ according to their mixed ratios of stroma 
and cells. We found that the mean ADC values ranged from 900 to 1600  (10–6  mm2/s) and minimum ADC values 
ranged from 550 to 1400  (10–6  mm2/s) which were consistent with previous large chordoma ADC  study16. Because 
the minimum ADC values reflect high cellular components of mass and affect mean ADC values, preoperative 
ADC measurements could be applied to predict tumor characteristics and aggressiveness for clival chordomas.
We have found that mean, maximum, and minimum ADC values in aggressive chordoma were significantly 
lower than in stable cases. If there were ADC components with values lower than the cutoff values in preopera-
tive tumor region of interests (ROIs), the tumor exhibited aggressive features even if a GTR or NTR had been 
achieved. If the mean and minimum ADC values in the tumor ROIs were higher than the cutoff values, the 
chordoma followed a stable course even with a PR. Subsequently, we could predict the prognosis of clival chor-
doma using preoperative ADC imaging.
In this study, cases with mean and minimum ADC values that were higher than the cutoff values showed 
significantly improved OS and PFS compared to those with lower values. Previous studies also correlated with 
our findings as cases with mean ADC values higher than 1494  (10–6  mm2/s) were significantly associated with 
(a)
(b)
(c)
Figure 1.  Comparison of ADC values between stable and aggressive chordoma  (10–6  mm2/s). There were 
significant differences between groups in (a) maximum ADC (P = 0.012), (b) mean ADC (P < 0.001), and (c) 
minimum ADC (P < 0.001).
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longer OS (P = 0.006)15. In terms of PFS, the predictive value of preoperative ADC imaging is high considering 
the notoriously high recurrence rates of clival chordomas. Our results confirmed that preoperative ADC values 
lower than cutoffs could significantly predict early tumor progression and recurrence as cases with mean ADC 
values lower than 1198  (10–6  mm2/s) showed a median PFS of 6 months. Therefore, a closer follow-up might be 
ideal for cases with a lower mean ADC value.
In the current study, we analyzed the cases further, based on other well-known prognostic factors such as 
EOR, histology, and the type of radiotherapy received. Maximal surgical resection has shown to improve PFS 
and OS. Our results also demonstrated that GTR/NTR significantly prolonged PFS and OS. However, a maximal 
surgical resection comes at a cost with neurological deficits ranging 33–80%3,31.
There has been controversy that chondroid chordoma is associated with better outcomes compared to classic 
 chordoma32,33. Some authors reported that the prognostic significance of histologic type is  unclear17,34,35. Hug 
and Slater even revealed that non-chondroid type chordoma correlated with longer  OS35. Although current study 
includes only two chondroid chordoma, our results confirmed that histologic type did not affect the prognosis. 
In addition, our study revealed that the same classic chordoma could have a different prognosis depending on 
the preoperative ADC values.
The question of which radiation modality is most effective for treating clival chordoma also remains 
 controversial10,11. In general, photon-based radiotherapy has been used as adjuvant treatment following surgery. 
However, some reported that conventional radiotherapy might not be effective, while others suggested that there 
is no benefit of using proton- over photon-based radiotherapy for the treatment of clival  chordomas2. Although 
our study has small sample size with relatively low statistical power, our results indicate that the radiation modal-
ity might not affect the prognosis of chordoma.
Our findings suggest that measurement of ADC can be a useful tool to predict prognosis of clivus chordoma 
and will help decide therapeutic plans. Regardless of ADC values, maximal safe surgical resection followed by 
conventional dose radiotherapy is recommended for treatment of clival chordoma. But if a chordoma belongs 
to the aggressive group, taking account of the higher possibility of tumor recurrence, we can consider total 
resection of the tumor followed by high dose radiotherapy which is higher than the conventional dose such as 
50 to  66Gy9. Furthermore, we recommend to follow up this aggressive group patient’s imaging more closely to 
find the early recurrence.
There are several limitations to this study. First, the study was retrospective in nature with a small sample size. 
Clival chordoma is a rare disease entity to conduct a large-scale, prospective study. Second, the follow-up period 
was not long enough considering the slow-growing nature of chordoma. Our follow-up might not have been 
longer that some  publications14,21, but our data was collected for more than 5 years. Lastly, two neurosurgeons and 
two neuroradiologists independently outlined the ROI with a freehand and measured ADC values. Regardless 
of these limitations, our results suggest that preoperative ADC values could be useful in predicting the progno-
sis of patients with clival chordomas. Previously, there have been a study highlighting the importance of ADC 
values in predicting aggressive of craniospinal axis  chordomas15. However, sacral chordomas can have different 
Figure 2.  ROC curves for ADC values differentiating aggressive chordoma from stable chordoma.
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ADC values compared to clival chordoma and higher ADC values may predict non-responsiveness to carbon 
ion  radiotherapy36. Therefore, it is important to distinguish clival chordomas from other spinal axis tumors for 
a specific and precise analysis. In this respect, our study is the first investigation to analyze the significance of 
ADC values confined to clival area.
In conclusion, ADC values have been reported to be diagnostic and prognostic for central nervous system 
tumors. We have found that mean, maximum, and minimum ADC values in aggressive chordoma were signifi-
cantly lower than in stable cases. Mean and minimum ADC values that were higher than the cutoff values showed 
significantly improved OS and PFS compared to those with lower values. Thus, preoperative MRI with diffusion 
sequence could be useful in predicting the outcome of patients with clival chordomas.
Methods
Study population. We conducted a retrospective single institution analysis of 32 patients who underwent 
surgery for clival chordomas between January 2012 and December 2019. Six patients without preoperative ADC 
imaging and values were excluded from the study. Of the 26 patients, a total of 30 surgical cases were performed 
and enrolled for the study. The cases were classified into either stable or aggressive group. The stable group 
was defined as having no evidence of tumor on consecutive magnetic resonance imaging (MRI) follow-ups. 
The aggressive tumor group was defined as evidence of tumor recurrence or progression on consecutive MRI 
follow-ups. ADC cutoff values for predicting the aggressiveness of clival chordoma were obtained by comparing 
preoperative ADC values between the two groups. The cutoff values were then analyzed for PFS and OS. Tumor 
recurrence was defined as a newly appearing mass on MRI at or near the surgical site. Tumor progression was 
defined as residual tumor size increase compared to prior MRI scan. The current study design and use of clinical 
data was approved by Gangnam severance hospital institutional review board (2020-0200-003). All experiments 
were carried out in accordance with approved guidelines. Informed consent was waived by the ethics committee 
(Gangnam Severance Hospital Institutional Review Board) for the entire study.
Gross total resection (GTR) was defined as complete tumor removal confirmed by the surgeon intraopera-
tively, and no evidence of residual tumor on 3-month and 1-year postoperative MRI scans. Near-total resection 
(NTR) was defined as more than 95% tumor resection with a thin layer of residual tumor on a neurovascular 
Table 2.  Univariable analysis of factors associated with PFS using Kaplan–Meier method.  ADC apparent 
diffusion coefficient, GTR gross total resection, MRI magnetic resonance imaging, NTR near-total resection, 
PFS progression free survival, PR partial resection, STR subtotal resection.
Explanatory variables Total No No. of events P-value
Age at first operation (year) 0.510
 Younger than 50 18 7
 50 or older 12 2
Histopathology 0.300
 Chondroid 2 1
 Classic 28 8
Adjuvant radiation therapy 0.701
 Proton 13 4
 Photon 17 5
MRI enhancement 0.136
 Heterogenous 20 8
 Little or none 10 1
Extent of tumor removal 0.001
 GTR + NTR 22 3
 STR + PR 8 6
Mean ADC  < 0.001
  > 1198  (10−6  mm2/s) 19 1
  ≤ 1198  (10−6  mm2/s) 11 8
Maximum ADC 0.017
  > 1695  (10−6  mm2/s) 14 1
  ≤ 1695  (10−6  mm2/s) 16 8
Minimum ADC  < 0.001
  > 895.5  (10−6  mm2/s) 17 0
  ≤ 895.5  (10−6  mm2/s) 13 9
Brainstem extension (at first MRI) 0.106
 Yes 24 9
 No 6 0
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(a) (b)
(d)(c)
(f)(e)
(h)(g)
P = 0.001
P = 0.017
P < 0.001 P < 0.001
P = 0.049
P = 0.221
P = 0.024 P = 0.003
Figure 3.  Kaplan–Meier curves using log-rank tests for overall survival and progression-free survival: (a) PFS 
according to extent of tumor resection; (b) PFS according to maximum ADC values; (c) PFS according to mean 
ADC values; (d) PFS according to minimum ADC values; (e) OS according to extent of tumor resection; (f) OS 
according to maximum ADC values; (g) OS according to mean ADC values; and (h) OS according to minimum 
ADC values.
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structure. Subtotal resection (STR) and partial resection (PR) were defined as 90–95% and less than 90% tumor 
resection on 3-month and 1-year postoperative MRI scans, respectively.
Analysis of MRI data. All patients were imaged with 1.5  T MRI device (Optima MR450w GEM, GE 
Healthcare, Milwaukee, WI, USA). Our MRI protocol for clival chordoma included routine diffusion-weighted 
sequences (TR/TE, 5500/66.1  ms; slice thickness/intersection gap, 4/1  mm; matrix size, 160 × 160; FOV, 
240 × 240  mm; three directions; b-value = 0 and 1000  s/mm2; number of averages = 2; number of slices = 35; 
bandwidth = 1953.12; acquisition time = 8  min 31  s), and T2-weighted fast-spin-echo sequences (repetition 
time/echo time (TR/TE), 5414/96 ms). After intravenous gadolinium-based contrast agent was administered at 
a dose of 0.1 mmol/kg body weight, axial fluid-attenuated inversion recovery sequences (TR/TE/inversion time 
(TI), 4000/80/2000 ms) and 3D T1 fast-spoiled gradient-recalled sequences (TR/TE, 8.2/3.2 ms; flip angle 12°; 
slice thickness, 1 mm; matrix size, 256 × 256; FOV, 220 × 220 mm) were taken sequentially. ADC values were 
automatically calculated by the operating console of the MRI device and were displayed as corresponding ADC 
maps.
Two neurosurgeons and two neuroradiologists independently outlined the region of interest (ROI) in free-
hand to obtain ADC values. An ROI was drawn on all axial ADC maps that included the tumor, while checking 
the T2-weighted and contrast enhanced T1-weighted images (Figs. 4 and 5). ADC values < 10 × 10–6  mm2/s were 
considered as artifacts. The mean, maximum, and minimum ADC values were obtained within this ROI for all 
axial sections that included the tumor and then calculated for the mean values. The ADC measurements were 
assessed for interobserver reliability using the interclass correlation coefficient. We also examined the enhance-
ment pattern of each tumor and classified as heterogeneous, little, or  none27.
Statistical analysis. Mean, maximum and minimum ADC values, patient age at the time of first surgery, 
sex, EOR, histopathology, and the type of adjuvant radiotherapy received were compared between the two 
groups using Fisher’s exact test. The cutoff ADC values were assessed using receiver operating characteristic 
(ROC) analysis to predict tumor aggressiveness. PFS and OS were analyzed using Kaplan–Meier curves and 
compared between the groups using log-rank tests with the following variables: mean, maximum and minimum 
ADC cutoff values, age at the time of the first surgery, histopathology, adjuvant radiation therapy, EOR, MRI 
enhancement pattern, and brainstem extension. All statistical analyses were performed using IBM SPSS statistics 
version 25.0 (IBM Corp, Armonk, NY, USA). Two-tailed P values < 0.05 were considered statistically significant.
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Figure 4.  A 37-year-old man was diagnosed with classic chordoma and placed in the aggressive group. (a) 
Preoperative contrast enhanced T1-weighted imaging showed a tumor compressing the brainstem. (b) The 
ROI is outlined in yellow on the ADC map and represents decreased water diffusivity (mean ADC 1107 × 10–6 
 mm2/s, minimum ADC 877 × 10–6  mm2/s). (c) Immediate postoperative contrast enhanced T1-weighted 
imaging shows gross total removal. Surgery was performed via the far lateral transcondylar approach. The 
patient received proton-based radiotherapy 3 months after surgery. (d) Contrast-enhanced T1 weighted imaging 
obtained 2 years later showed an increase of the mass adjacent to the previous surgical site. The patient died of 
disease 7 months after the last MRI due to meningitis.
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